Delisting Procedures in Hong Kong: HKEX's Three-Stage Cancellation Process

The Hong Kong Stock Exchange (HKEX) has tightened its delisting regime to an extent that makes the pre-2018 framework virtually unrecognisable. As of 2025, the three-stage cancellation process — codified under the Listing Rules — has become the primary mechanism for removing issuers that fail to maintain a viable public float, adequate operations, or regulatory compliance. This shift, driven by the HKEX’s 2018 Listing Reform and subsequent 2024 amendments to Chapter 6 of the Main Board Rules, now forces issuers into a rigid timeline with no automatic right to appeal after the third stage. For sponsors, company secretaries, and CFOs managing distressed listed entities, understanding this process is no longer optional: it is a matter of survival for the listing status.

The Three-Stage Framework: From Suspension to Cancellation

The HKEX’s delisting process for Main Board issuers operates through a sequential three-stage framework, formally outlined in Listing Rules Chapter 6 and Practice Note 17. Stage One begins with a trading suspension, typically triggered by a failure to meet ongoing listing criteria — such as a public float below 25% (Rule 8.08), insufficient revenue or assets (Rule 13.24), or unresolved regulatory breaches. The exchange issues a “resumption guidance” letter, setting a specific remediation period, usually 6 to 12 months, during which the issuer must address the deficiency. As of Q1 2025, the average Stage One period for issuers suspended in 2024 was 8.4 months, according to HKEX’s Listing Committee statistics.

Stage Two commences if the issuer fails to comply with the resumption guidance within the stipulated period. The HKEX issues a “delisting notice” under Rule 6.01A, granting the issuer a final 6-month cure period. During this phase, the exchange may impose additional conditions, such as a requirement to appoint a compliance advisor or to demonstrate a sustainable business model. Data from the HKEX’s 2024 Annual Review shows that 42% of issuers entering Stage Two were subsequently cancelled, while 31% successfully resumed trading after meeting all conditions.

Stage Three is the final step: the HKEX publishes a “cancellation notice” under Rule 6.10, after which the issuer’s securities are removed from the Main Board. The exchange provides no further cure period at this point, and the issuer’s only recourse is a formal review by the Listing Committee under Rule 2B.06. In 2024, the Listing Committee upheld cancellations in 89% of review applications, based on HKEX’s published decisions. The entire process, from suspension to cancellation, averages 18 to 24 months, though complex cases involving fraud investigations can extend beyond 36 months.

Stage One: Suspension and Resumption Guidance

The trigger for Stage One is a trading suspension, which the HKEX imposes under Rule 6.05 when an issuer fails to maintain listing eligibility. Common triggers include a public float falling below the 25% minimum (Rule 8.08), a failure to publish financial results within the prescribed timeframe (Rule 13.46), or the appointment of a liquidator or receiver under the Companies Ordinance (Cap. 622). In 2024, the HKEX suspended 37 Main Board issuers, of which 22 were due to financial reporting delays, 9 to public float issues, and 6 to regulatory investigations, per the HKEX’s 2024 Market Statistics.

Upon suspension, the HKEX issues a “resumption guidance” letter under Practice Note 17, specifying the exact conditions the issuer must satisfy to resume trading. These conditions are tailored to the specific deficiency but typically include: (i) publishing all outstanding financial statements; (ii) demonstrating adequate internal controls; (iii) resolving any regulatory breaches; and (iv) confirming the issuer’s ability to continue as a going concern. The issuer must submit a resumption proposal within 3 months of the suspension date, or the HKEX may accelerate the timeline.

The cure period for Stage One is usually 6 to 12 months, but the HKEX retains discretion to extend it under exceptional circumstances, such as a court-ordered moratorium. For example, in the 2023 case of Re China Forestry Holdings Limited (HKEX Listing Decision 2023-05), the exchange granted a 12-month extension due to the issuer’s ongoing restructuring under the Companies Ordinance. However, extensions are rare: in 2024, only 4 of 37 suspended issuers received extensions beyond the initial period.

Stage Two: Delisting Notice and Final Cure Period

If the issuer fails to satisfy the resumption guidance within the Stage One period, the HKEX issues a “delisting notice” under Rule 6.01A. This notice triggers Stage Two, a final 6-month cure period during which the issuer must remedy all outstanding deficiencies. The HKEX’s Listing Committee, in its 2024 Guidance Note on Delisting, emphasised that Stage Two is not a negotiation phase: the exchange will not accept partial compliance or conditional resumption proposals.

During Stage Two, the issuer must file a comprehensive resumption application, including: (i) audited financial statements for the most recent two financial years; (ii) a business plan demonstrating sustainable revenue and assets under Rule 13.24; (iii) a legal opinion confirming compliance with all applicable laws; and (iv) a confirmation from the sponsor that internal controls are adequate. The HKEX’s Listing Department reviews the application within 30 business days, after which it either approves resumption or proceeds to Stage Three.

Data from the HKEX’s 2024 Annual Review indicates that 31% of issuers in Stage Two successfully resumed trading, while 27% remained suspended pending further review, and 42% were cancelled. The average time from Stage Two initiation to cancellation was 7.2 months, reflecting the exchange’s push for faster resolution. Issuers that fail to file a complete resumption application within the 6-month period are automatically moved to Stage Three, with no further grace period.

Stage Three: Cancellation and Review Rights

Stage Three is the final step, triggered when the issuer fails to satisfy the conditions of the delisting notice. The HKEX publishes a “cancellation notice” under Rule 6.10, which takes effect 14 calendar days after publication. The issuer’s securities are then removed from the Main Board, and trading ceases permanently. As of 2025, the HKEX has cancelled 14 Main Board issuers in the first quarter alone, compared to 52 cancellations in the full year 2024, per the HKEX’s Monthly Market Reports.

The issuer retains a single right of review under Rule 2B.06, which allows it to appeal the cancellation to the Listing Committee within 10 business days of the cancellation notice. The review is conducted on a de novo basis, meaning the committee considers all evidence afresh, but the issuer bears the burden of proof to demonstrate that the cancellation was unreasonable. In 2024, the Listing Committee upheld cancellations in 89% of review applications, with only 3 issuers successfully reversing the decision.

Notably, the HKEX’s review process does not suspend the cancellation timeline. If the issuer files a review application, the cancellation is stayed pending the committee’s decision, but the issuer remains suspended. The entire review process typically takes 4 to 6 weeks, during which the issuer must continue to meet all disclosure obligations under the Listing Rules. Failure to do so may result in the committee dismissing the application without a hearing.

Key Regulatory Triggers for Delisting

The HKEX’s delisting framework is not limited to financial distress; it encompasses a broad range of regulatory triggers that can initiate the three-stage process. The most common triggers, as outlined in the HKEX’s 2024 Guidance Note on Delisting, include: (i) failure to maintain a sufficient public float under Rule 8.08; (ii) inability to carry on a viable business under Rule 13.24; (iii) non-compliance with financial reporting requirements under Rule 13.46; (iv) regulatory investigations or enforcement actions; and (v) insolvency or winding-up proceedings under the Companies Ordinance (Cap. 622).

Public Float and Minimum Capital Requirements

Rule 8.08 requires that at least 25% of an issuer’s total issued shares be held by the public at all times. If the public float falls below this threshold, the HKEX may suspend trading under Rule 6.05 and initiate Stage One. In 2024, the HKEX suspended 9 issuers for public float deficiencies, with the average shortfall being 8.3 percentage points below the 25% minimum, per the HKEX’s 2024 Market Statistics. Issuers have 30 business days to restore the public float through a placing or rights issue, or face progression to Stage Two.

Business Viability Under Rule 13.24

Rule 13.24 requires that an issuer’s business operations be “sufficient to warrant the continued listing of its securities.” The HKEX assesses this based on revenue, assets, and cash flow. In practice, the exchange considers an issuer to have failed this test if it has no revenue for two consecutive financial years or if its total assets are less than HKD 100 million. In 2024, the HKEX suspended 14 issuers under Rule 13.24, of which 8 were subsequently cancelled. The average time from suspension to cancellation for these issuers was 15.3 months, shorter than the overall average due to the lack of a viable business plan.

Financial Reporting and Disclosure Failures

Failure to publish annual or interim financial results within the prescribed deadlines triggers an automatic suspension under Rule 6.05. In 2024, 22 issuers were suspended for financial reporting delays, with the average delay being 4.7 months beyond the deadline. The HKEX’s 2024 Annual Review noted that issuers with persistent reporting failures — defined as three or more consecutive breaches — are more likely to be moved directly to Stage Two without a full Stage One cure period.

Practical Implications for Issuers and Advisors

For CFOs, company secretaries, and sponsors managing issuers at risk of delisting, the three-stage process imposes strict timelines and high compliance costs. The first practical implication is the need for early detection: issuers should monitor their public float, financial reporting deadlines, and business viability on a quarterly basis. The HKEX’s 2024 Guidance Note recommends that issuers conduct a “listing status review” at least twice a year, with a focus on Rule 8.08 and Rule 13.24 compliance.

The second implication is the cost of compliance during the cure period. Issuers in Stage One or Stage Two must engage a sponsor to prepare the resumption application, which typically costs between HKD 2 million and HKD 5 million for a standard case, based on market estimates from 2024. Additionally, the issuer must appoint a compliance advisor under Rule 3A.19, at an annual cost of HKD 500,000 to HKD 1 million. For issuers with limited cash flow, these costs can be prohibitive, leading to voluntary cancellation.

The third implication is the reputational damage associated with a delisting. Once an issuer is cancelled, its securities are removed from the Main Board and cannot be traded on any recognised exchange in Hong Kong. The issuer may apply for a relisting under Rule 9.01, but the HKEX’s 2024 Policy Statement on Relisting notes that cancelled issuers face a 12-month waiting period and must satisfy all initial listing requirements anew. In 2024, only 2 cancelled issuers successfully relisted, compared to 52 cancellations.

Actionable Takeaways

• Monitor public float and financial reporting deadlines quarterly to avoid triggering Stage One suspension under Rule 8.08 or Rule 13.46.
• Engage a sponsor immediately upon receiving a resumption guidance letter to prepare a comprehensive resumption application within the 6-month cure period.
• Budget for compliance costs of HKD 2.5 million to HKD 6 million during the Stage One and Stage Two periods, including sponsor fees and compliance advisor retainers.
• File a review application under Rule 2B.06 within 10 business days of a cancellation notice, but prepare for a 89% likelihood of the decision being upheld based on 2024 data.
• Consider voluntary cancellation under Rule 6.15 if the issuer cannot meet the resumption conditions, as this preserves the option to relist after a 12-month waiting period.